The recently popular multiplex recombination (mIHC) is a tissue detection technology developed from the standard IHC that detects a single target. It can detect multiple targets simultaneously in situ on one slice. mIHC technology can be said to be a powerful tool for studying complex samples such as tumor microenvironments. It can simultaneously obtain tissue tumor markers, cell status, immune cell typing, immune regulation, matrix and other information, and analyze the full picture of tumor immune characteristics. The significance of
mIHC does not lie in how high the multiplicity is or how cool the images are. What is important is that mIHC technology can play a very critical role in promoting tumor immunology and oncology research, promoting personalized medicine, and assisting in the discovery of biomarkers.
01 How does mIHC contribute to new discoveries in tumor immunology and oncology research?
02 How does mIHC promote personalized medicine in tumor treatment, help doctors make the best diagnosis and treatment choices, and improve patient survival rates?
03 How does mIHC help biomarker discovery and improve the success rate of clinical trials?
04 mIHC is too expensive. Is there an economical and efficient mIHC technology?
In response to the above issues, Abcam invited 4 experts from clinical, academic and industrial circles to share their latest results and insights at this seminar.
Scan the QR code to participate in the seminar, listen to the sharing of experts,
and obtain the abcam multiple recombinant antibody recommended list
(this list collects information on multiple mIHC platforms such as OpalTM TSA , IMCTM, CODEX® and other frequently used abcam antibody product numbers and citations in the industry, as well as recommendations for antibody product numbers verified by abcam and its collaborators, saving time in your panel design and condition optimization work, and reducing unnecessary experimental exploration)
Guests and Speech Titles
Joe Yeong
Doctor of Medicine and Surgery | Singapore General Hospital; A*STAR Institute of Molecular and Cell Biology
The era beyond PD-L1: What can we do to help oncologists colleagues and patients further for personalized medicine? (In addition to PD-L1, what else can further help oncologists and patients achieve personalized medicine?)
The requirements for detection technology in clinical diagnosis and treatment include: high correlation with clinical performance, automatability, affordable cost/time cost, and tissue saving. mIHC technology perfectly matches these requirements. Dr. Joe will share the story of how his team used mIHC technology to discover that CD39 and CD38 can be used as biomarkers for immunotherapy in the diagnosis and treatment of non-small cell lung cancer and liver cancer respectively, and further defined the diagnosis and treatment panel and the prediction efficacy panel.
Leeat Keren
Ph.D. in Molecular and Cellular Biology | Weizmann Institute of Science, Israel
Love thy neighbor – unraveling the tumor-immune microenvironment using multiplexed imaging (Using multiplexed imaging to reveal the tumor immune microenvironment)
Which immune cell populations appear in different patients? What do these differences mean? Which molecules expressed by cells can serve as immune checkpoints? Which patients could benefit from treatment? In response to the above issues, Dr. Leeat will share her story of using mIHC technology to visualize the composition of immune cells in the tumor microenvironment and discovering a new type with better prognosis in triple-negative breast cancer research.
Jacques Fieschi
PhD in Immunology | HalioDx Vice President of R&D, France
Bridging translation research to clinical application: Brightplex, a validated multiplex IHC technology to spatially explore the TME (Brightplex, a validated multiplex IHC technology platform for tumor microenvironment research - a bridge between translational research and clinical application)
Dr. Jacques will introduce the brightfield chromogenic mIHC and spatial analysis platform Brightplex® How to support tumor immunology research and clinical biomarker discovery.
Adrien Guillot
Researcher | Charité Universitätsmedizin Berlin, Germany
Multiplex immunohistochemistry on a single archival formalin-fixed paraffin-embedded tissue section (Multiplex immunohistochemical staining of a single formalin-fixed paraffin-embedded tissue section)
Dr. Adrien will share a cost-effective research method, without the need for special equipment and reagents, into liver fibrosis, steatohepatitis, and hepatocellular carcinoma (HCC) through mIHC staining based on sequential immunostaining and antibody stripping, combined with free software for digital image processing and analysis. The liver immune microenvironment was studied in mouse models as well as in human patient samples with chronic liver disease [1].
Related product recommendations
Abcam multiplex chemical product series 1
☞10000 Multiple IHC validated catalog products and ☞ Partial OpalTM TSA mIHC validated antibody .
Abcam multiplex recombinant product series 2
☞ More than 4000 IHC-validated carrier-free formats of antibodies , suitable for ultra-multiple staining schemes based on oligonucleotide (InSituPlex®, CODEX®, GeoMx®DSP and other technologies) or metal atom-conjugated antibodies (IMC™).
Abcam multiplex chemical product series three
☞ direct-labeled primary antibody verified by IHC. Using directly labeled primary antibodies can simplify experimental procedures and eliminate the need to use fluorescent secondary antibodies.
Please go to the Abcam official website (www.abcam.cn) to view the above products
Note: InSituPlex® is a registered trademark of Ultivue; Opal™ is a multi-label immunohistochemical staining protocol of Akoya Biosciences; CODEX® is a registered trademark of Akoya Biosciences; GeoMx® is NanoString The company's registered trademark; IMC™ is Fluidigm's imaging mass cytometry system. Brightplex® is a registered trademark of Veracyte (HalioDx has now been acquired by Veracyte).
Related literature
[1] Adrien Guillot 1, Marlene S Kohlhepp, etc.. Deciphering the Immune Microenvironment on A Single Archival Formalin-Fixed Paraffin-Embedded Tissue Section by An Immediately Implementable Multiplex Fluorescence Immunostaining Protocol. Cancers (Basel). 2020 Aug 28;12(9):2449. DOI: 10.3390/cancers12092449
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-